Omnicell (NASDAQ:OMCL) Price Target Raised to $44.00 at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its price target lifted by JPMorgan Chase & Co. from $37.00 to $44.00 in a research note released on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts also recently commented on OMCL. Barclays upped their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Craig Hallum upped their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Bank of America restated a “neutral” rating and issued a $57.00 target price (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Finally, Benchmark reiterated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Stock Up 3.6 %

Omnicell stock opened at $45.69 on Thursday. The stock has a 50-day moving average price of $44.27 and a 200 day moving average price of $37.36. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -117.15, a price-to-earnings-growth ratio of 37.10 and a beta of 0.81. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Institutional Trading of Omnicell

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. raised its stake in shares of Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares during the period. Federated Hermes Inc. raised its position in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares during the period. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell during the third quarter worth $32,721,000. Pacer Advisors Inc. lifted its holdings in Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.